干扰素β药物市场：依产品类型、给药途径、配销通路及地区

2023年干扰素β产品的全球市场规模预估为42.2亿美元，预测期内（2023-2030年）年复合成长率为4.0%。

干扰素β产品的全球市场占有率（%），依产品类型，2023年

干扰素β用于治疗復发型多发性硬化症 (MS)，包括临床孤立症候群、復发缓解型疾病和活动性进行性疾病。儘管这种药物不能完全治癒这种疾病，但它可以减缓某些残疾症状的进展并减少復发次数。干扰素是人体内产生的天然物质，可以对抗感染疾病。干扰素β製剂分为干扰素β-1A、干扰素β-1B、聚乙二醇化干扰素β-1A。

市场动态

多发性硬化症是一种神经系统疾病，会导致广泛的残疾，最常发生在 20 岁至 50 岁之间。根据多发性硬化症基金会（一个拥有 501 名成员的多发性硬化症患者及其家人的非营利组织）的数据，2020 年 1 月，这种自体自体免疫疾病影响了 250 万人，全球年度发生率约为每10 万人中7 例。患病范围为每 10 万人 50 至 120 人，取决于种族和地理纬度。此外，根据多发性硬化症基金会2021年发布的资料，美国估计有40万人患有此病，每週诊断出约200例新病例。根据总公司美国加州的健康资讯提供者 Healthline Media 2022 年 3 月的研究，多发性硬化症是继充血性心臟衰竭之后的第二大常见疾病，每位患者年度的直接和间接医疗费用最高，从8,528 美元起至 54,244 美元。因此，多发性硬化症患病的增加是推动全球干扰素β製剂市场成长的主要要素。

本研究的主要特点

• 本报告对全球干扰素β药物市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030年）的市场规模和年复合成长率。
• 它还揭示了各个细分市场的潜在收入机会，并为该市场说明了一系列有吸引力的投资提案。
• 它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
• 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球干扰素 Beta 製药市场的主要企业。
• 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
• 全球干扰素β製剂市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 相关人员可以透过用于分析全球干扰素β药物市场的各种策略矩阵来促进他们的决策。

目录

第1章调查目的和假设

• 这项研究的目的
• 假设
• 简称

第2章市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第3章市场动态、法规及趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 市场机会
• 影响分析
• 近期产品发布
• 流行病学
• 合併、收购和合作
• 法规场景
• 主要进展
• PEST分析

第4章全球干扰素β製剂市场，COVID-19的影响分析

• 经济影响
• 新型冠状病毒（COVID-19）的流行病学
• 对需求和供给的影响

第5章全球干扰素β药物市场，依产品类型，2018-2030

• 干扰素β-1A
• 干扰素β-1B
• 聚乙二醇干扰素β-1A

第6章全球干扰素β药物市场，依给药途径，2018-2030

• 肌肉注射
• 皮下的
• 静脉

第7章全球干扰素β药物市场，依配销通路，2018-2030

• 医院药房
• 零售药房
• 网路药房

第8章2018-2030年全球干扰素β製剂市场（按地区）

• 北美洲
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲
• 欧洲
• 英国
• 德国
• 义大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 中国
• 印度
• 日本
• ASEAN
• 澳洲
• 韩国
• 其他亚太地区
• 中东
• GCC
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中部非洲
• 南非

第9章竞争形势

• Biogen
• Merck KGaA
• Novartis AG
• Bayer AG

第10章章

• 调查方法
• 关于出版商

The global interferon beta drugs market is estimated to be valued at US$ 4.22 Bn in 2023 and is expected to exhibit a CAGR of 4.0% during the forecast period (2023-2030).

Global Interferon Beta Drugs Market Share (%), by Product Type, 2023

Interferon beta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug does not completely cure the condition, but it slows down the progression of some of the disabling effects and decreases the number of relapses. Interferons are natural substances produced in the human body to help fight infections. Interferon beta drugs are categorized as Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A.

Market Dynamics

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group of 20-50 years. According to the Multiple Sclerosis Foundation, a 501 non-profit organization benefiting people with multiple sclerosis and their families, in January 2020, this autoimmune condition affected 2.5 million people with an annual global incidence of around 7 cases per 100,000 people. The study also states that prevalence rates vary between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000. Moreover, according to the data published by the Multiple Sclerosis Foundation in 2021, an estimated 400,000 people live with the disease in the U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, a provider of health information headquartered in California, U.S., in March 2022, multiple sclerosis ranks second after congestive heart failure, with direct and indirect health care costs ranging from US$8,528 to US$54,244 per patient per year. Thus, the increasing prevalence of multiple sclerosis is a major factor driving the growth of the global interferon beta drugs market.

Key features of the study:

• This report provides an in-depth analysis of the global interferon beta drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global interferon beta drugs market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen, Merck KGaA, Novartis AG and Bayer AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global interferon beta drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interferon beta drugs market.

Detailed Segmentation:

• Global Interferon Beta Drugs Market, By Product Type:
  • Interferon Beta-1A
  • Interferon Beta-1B
  • Peginterferon Beta-1A
• Global Interferon Beta Drugs Market, By Route of Administration:
  • Intramuscular
  • Subcutaneous
  • Intravenous
• Global Interferon Beta Drugs Market, By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Interferon Beta Drugs Market, By Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America

Middle East & Africa

• Company Profiles
  • Biogen
  • Merck KGaA
  • Novartis AG
  • Bayer AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Route Of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Interferon Beta Drugs Market- COVID-19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Interferon Beta Drugs Market, By Product Type, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Interferon Beta-1A
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Interferon Beta-1B
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Peginterferon Beta-1A
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Interferon Beta Drugs Market, By Route Of Administration, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Intramuscular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Interferon Beta Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018-2030
  • Segment Trends
• Hospitals Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Interferon Beta Drugs Market, By Region, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2018-2030, (US$ Bn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us